CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
Sign Up to like & getrecommendations! Published in 2023 at "Oncology Letters"
DOI: 10.3892/ol.2023.13822
Abstract: Anti-CD19 chimeric antigen receptor (CAR)-T cells have improved the outcomes of patients with B cell leukemia and lymphoma. However, their applications and positive outcomes remain limited. CAR-T cells are currently restricted to autologous blood as… read more here.
Keywords: car; anti cd19; cd22 bispecific; cd19 cd22 ... See more keywords